Lead Story
Vienna physicists demonstrate first self-stabilizing nuclear clock
Physicists at TU Wien and Germany's PTB reported in Nature on October 7 the first nuclear clock that keeps itself stable: a system using thorium-229 nuclei to actively correct the laser that drives it, which ran for more than 24 hours without manual intervention. The prototype doesn't yet beat the best optical atomic clocks, and a preliminary dark-matter search using the device found no signal, but researchers called it a strong proof of concept for a brand-new class of timekeeper. Nuclear clocks are expected to eventually be far more resistant to outside interference than today's atomic clocks, with potential uses from more precise satellite navigation to tests of fundamental physics.
Read more →Lead Story
Vienna physicists demonstrate first self-stabilizing nuclear clock
Physicists at TU Wien and Germany's PTB reported in Nature on October 7 the first nuclear clock that keeps itself stable: a system using thorium-229 nuclei to actively correct the laser that drives it, which ran for more than 24 hours without manual intervention. The prototype doesn't yet beat the best optical atomic clocks, and a preliminary dark-matter search using the device found no signal, but researchers called it a strong proof of concept for a brand-new class of timekeeper. Nuclear clocks are expected to eventually be far more resistant to outside interference than today's atomic clocks, with potential uses from more precise satellite navigation to tests of fundamental physics.
Nobel-winning optogenetics tools give blind patients partial vision in new trial
The 2026 Nobel Prize in Physiology or Medicine, announced October 5, went to Karl Deisseroth, Peter Hegemann and Georg Nagel for discovering the light-gated ion channels behind optogenetics, a technique now used in labs worldwide to switch individual nerve cells on or off with light. Two days later, a study in the New England Journal of Medicine showed the science paying off clinically: an optogenetic gene therapy paired with camera-equipped goggles improved light sensitivity in seven of ten people with advanced retinitis pigmentosa, with six gains large enough to count as clinically meaningful. The therapy gives surviving retinal cells a light-sensitive protein, while the goggles convert a captured scene into light signals those cells can read; the treatment was generally well tolerated.
Read more →Nobel-winning optogenetics tools give blind patients partial vision in new trial
The 2026 Nobel Prize in Physiology or Medicine, announced October 5, went to Karl Deisseroth, Peter Hegemann and Georg Nagel for discovering the light-gated ion channels behind optogenetics, a technique now used in labs worldwide to switch individual nerve cells on or off with light. Two days later, a study in the New England Journal of Medicine showed the science paying off clinically: an optogenetic gene therapy paired with camera-equipped goggles improved light sensitivity in seven of ten people with advanced retinitis pigmentosa, with six gains large enough to count as clinically meaningful. The therapy gives surviving retinal cells a light-sensitive protein, while the goggles convert a captured scene into light signals those cells can read; the treatment was generally well tolerated.
CAR T-cell therapy drives complete responses in 89% of relapsed amyloidosis patients
An October 1 interim readout from the NEXICART-2 trial found that Immix Biopharma's CAR T-cell therapy NXC-201 produced an independently confirmed complete response rate of 89% among 45 evaluable patients with relapsed or refractory AL amyloidosis, a rare and often fatal disease in which misfolded proteins damage the heart, kidneys and other organs. Among the most recently analysed group of 25 patients, 21 achieved complete response outright and the remaining four tested negative for minimal residual disease in bone marrow. The rate has climbed from 75% reported at the American Society of Hematology meeting in late 2025, and the company is working toward a regulatory filing.
Read more →CAR T-cell therapy drives complete responses in 89% of relapsed amyloidosis patients
An October 1 interim readout from the NEXICART-2 trial found that Immix Biopharma's CAR T-cell therapy NXC-201 produced an independently confirmed complete response rate of 89% among 45 evaluable patients with relapsed or refractory AL amyloidosis, a rare and often fatal disease in which misfolded proteins damage the heart, kidneys and other organs. Among the most recently analysed group of 25 patients, 21 achieved complete response outright and the remaining four tested negative for minimal residual disease in bone marrow. The rate has climbed from 75% reported at the American Society of Hematology meeting in late 2025, and the company is working toward a regulatory filing.
Engineered immune cells clear a child's liver cancer, with regression holding a year later
Doctors at Texas Children's Hospital, Baylor College of Medicine and Seattle Children's reported in the New England Journal of Medicine that a 3-year-old boy's hepatoblastoma, a liver cancer that had spread to his lungs and stopped responding to three rounds of chemotherapy, fully resolved after two outpatient infusions of an experimental CAR T-cell therapy. The cells, engineered to target the GPC3 protein and armed with the immune signals IL-15 and IL-21, produced a partial response after the first infusion and full resolution of the metastatic disease after the second, given from the Phase 1 CARE study. The boy has shown no sign of disease for a year, and the treatment caused no dose-limiting toxicities or cytokine release syndrome; researchers caution that one case is not proof the therapy works broadly and are now planning larger trials.
Read more →Engineered immune cells clear a child's liver cancer, with regression holding a year later
Doctors at Texas Children's Hospital, Baylor College of Medicine and Seattle Children's reported in the New England Journal of Medicine that a 3-year-old boy's hepatoblastoma, a liver cancer that had spread to his lungs and stopped responding to three rounds of chemotherapy, fully resolved after two outpatient infusions of an experimental CAR T-cell therapy. The cells, engineered to target the GPC3 protein and armed with the immune signals IL-15 and IL-21, produced a partial response after the first infusion and full resolution of the metastatic disease after the second, given from the Phase 1 CARE study. The boy has shown no sign of disease for a year, and the treatment caused no dose-limiting toxicities or cytokine release syndrome; researchers caution that one case is not proof the therapy works broadly and are now planning larger trials.
Amazon deforestation falls to its lowest level in over a decade
Brazilian satellite data released this year show deforestation alerts in the Amazon for the August 2025-to-July 2026 monitoring cycle totalled about 2,874 square kilometres, a 36.9% drop from the previous year and the lowest figure since the current DETER monitoring system began in 2015. Separate first-half-of-2026 data showed 1,295 square kilometres cleared from January to June, down 38% year-on-year. Environmental groups welcomed the trend but warned it remains fragile: wildfires in the region rose more than 30% even as clearing fell, and scientists cautioned that a forecast 'super' El Nino-driven drought through early 2027 could threaten the gains.
Read more →Amazon deforestation falls to its lowest level in over a decade
Brazilian satellite data released this year show deforestation alerts in the Amazon for the August 2025-to-July 2026 monitoring cycle totalled about 2,874 square kilometres, a 36.9% drop from the previous year and the lowest figure since the current DETER monitoring system began in 2015. Separate first-half-of-2026 data showed 1,295 square kilometres cleared from January to June, down 38% year-on-year. Environmental groups welcomed the trend but warned it remains fragile: wildfires in the region rose more than 30% even as clearing fell, and scientists cautioned that a forecast 'super' El Nino-driven drought through early 2027 could threaten the gains.